Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ:AMGN)

298.50 +16.30 (+5.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline
Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share. 
Via Benzinga
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Uncovering Potential: Amgen's Earnings Preview
 
Via Benzinga
AMGEN INC (NASDAQ:AMGN) Shows Strong Technical Breakout Potential with High Setup Rating
AMGEN INC (AMGN) shows strong breakout potential with a Technical Rating of 7 and Setup Rating of 9, signaling bullish momentum and a tight consolidation pattern. 
Via Chartmill
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far. 
Via Benzinga
Topics Government World Trade
Amgen (AMGN) Q2 Profit Jumps 21%
Via The Motley Fool
Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue... 
Via StockStory
What Analysts Are Saying About Amgen Stock
 
Via Benzinga
This Is What Whales Are Betting On Amgen
 
Via Benzinga
What Does the Market Think About Amgen?
 
Via Benzinga
Amgen Inc (NASDAQ:AMGN) Surpasses Q2 2025 Earnings Estimates Despite Muted Market Reaction
Amgen beats Q2 2025 earnings with $9.179B revenue and $6.02 EPS, but shares dip slightly as market reaction remains muted. CEO highlights growth in biosimilars and raised full-year guidance. 
Via Chartmill
Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News?
Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout. 
Via Investor's Business Daily
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Stock Market Today: US Stock Futures Inch Higher, As Analysts Warn of Volatile August—AMD, Pfizer, Caterpillar In Focus
U.S. stock futures are inching higher on Tuesday, following a strong rally on Monday, with major benchmark indices in the green. 
Via Benzinga
Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow
Via StockStory
Topics Artificial Intelligence World Trade
Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics
 
Via Benzinga
Topics Economy Government
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast. 
Via Benzinga
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors. 
Via The Motley Fool
Topics Intellectual Property
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
2 Reasons to Like AMGN and 1 to Stay Skeptical
Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up... 
Via StockStory
Topics Government Stocks
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
How Does Nvidia's Reaching $4 Trillion in Market Cap Impact the S&P 500, Nasdaq-100, and Dow Jones?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'
 
Via Benzinga
Topics Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.